Skip to main content
. 2013 Sep;27(9):3827–3836. doi: 10.1096/fj.13-228858

Figure 8.

Figure 8.

Effect of EP4 stimulation on COX2 and mPGES-1 expression in Mtb-infected Mφs. A) Top panel: Western blot of COX2 and mPGES-1 at 24 h after infection in H37Ra- and H37Rv (MOI 10:1)-infected Mφs treated with the EP4 agonist ONO-AE1-329 (1 or 10 μM; n=3). Bottom panels: quantization of COX2 and mPGES-1 from Western blot panel. Intensity of the COX2 and mPGES-1 protein was normalized to that of GAPDH and presented as fold change relative to only H37Ra-infected Mφs. Values are means of 3 independent experiments. B) Top panel: Western blot of COX2 and mPGES-1 in Mφs treated with the EP4 agonist ONO-AE1-329 (1 or 10 μM) and the TLR1/2 agonist Pam3CSK4 (10 μg/ml) at 24 h after treatment (n=3). Bottom panel: quantization of COX2 and mPGES-1 protein in Western blot analysis. Intensity of the COX2 protein and mPGES-1 protein was normalized to that of GAPDH and presented as fold change relative to Mφs treated with Pam3CSK4 only. Values are means ± sem of 3 independent experiments. C) Relative gene expression of COX2 and mPGES-1 in ONO-AE1-329 (10 μM)-treated H37Rv (MOI 10:1)-infected Mφs at 24 h after infection. (n=3; means±sem). EP2 agonist butaprost has a minimal effect. *P < 0.05 vs. Mφs infected with H37Rv only. D) Down-regulation of the relative gene expression of COX2 and mPGES-1 in ONO-AE1-329 (10 μM)-treated Mφs infected with H37Rv (MOI 10:1) by the EP4 antagonist AH23848 (10 μM; n=3; means±sem). *P < 0.05 vs. Mφs infected with H37Rv only; ^P < 0.05 vs. ONO-AE1-329-treated Mφs infected with H37Rv.